NEWARK,
Calif., Dec. 1, 2022 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company")
today announced that Dinesh V.
Patel, Ph.D., President and Chief Executive Officer, will
participate in a fireside chat presentation and host one-on-one
meetings with investors at the JMP Securities Hematology and
Oncology Summit, a virtual investor event taking place December 6-7, 2022.
Presentation Details:
Date: December 6, 2022
Time: 11:40 a.m. ET / 8:40 a.m. PT
A webcast of the event will be available for 90 days on the
Investors section of the Protagonist Therapeutics website at
http://investors.protagonist-inc.com/.
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with
peptide-based new chemical entities rusfertide and PN-235 in
advanced stages of clinical development, both derived from the
Company's proprietary technology platform. Rusfertide, a mimetic of
the natural hormone hepcidin, is the Company's lead drug candidate
currently in a global Phase 3 stage of development. The VERIFY
(Phase 3) and REVIVE (Phase 2) studies of rusfertide in
polycythemia vera are ongoing. Protagonist owns all marketing
rights to rusfertide.
Protagonist has partnered with Janssen Biotech, Inc. on the
development of PN-235 (JNJ-77242113) in moderate-to-severe
psoriasis and inflammatory bowel disease. PN-235 is currently in
multiple studies in psoriasis, led by Janssen.
Protagonist is headquartered in Newark, California. For more information on
Protagonist, please visit the Company's website at
www.protagonist-inc.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-jmp-securities-hematology-and-oncology-summit-301691132.html
SOURCE Protagonist Therapeutics, Inc.